{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T21:24:23Z","timestamp":1794777863072,"version":"4.9.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ijantimicag.2022.106629","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T02:20:46Z","timestamp":1656037246000},"page":"106629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Immunogenicity of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine in people living with HIV on combination antiretroviral therapy"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8481-5455","authenticated-orcid":false,"given":"Hannah M.","family":"Garcia Garrido","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny L.","family":"Schnyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beheshta","family":"Haydari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert M.","family":"Vollaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9828-4459","authenticated-orcid":false,"given":"Michael W.T.","family":"Tanck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godelieve J.","family":"de Bree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3410-9912","authenticated-orcid":false,"given":"Bob","family":"Meek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0046-1099","authenticated-orcid":false,"given":"Martin P.","family":"Grobusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Goorhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2022.106629_bib0001","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/cid\/ciz728","article-title":"Incidence and risk factors for invasive pneumococcal disease and community-acquired pneumonia in human immunodeficiency virus-infected individuals in a high-income setting","volume":"71","author":"Garcia Garrido","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0002","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jaut.2017.03.011","article-title":"Vaccination recommendations for the adult immunosuppressed patient: a systematic review and comprehensive field synopsis","volume":"80","author":"Lopez","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0003","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1016\/j.vaccine.2013.04.085","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0004","first-page":"29","article-title":"Immunogenicity of pneumococcal vaccination in HIV infected individuals: a systematic review and meta-analysis","author":"Garcia Garrido","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0005","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/cid\/cit937","article-title":"Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis","volume":"58","author":"Kerneis","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0006","doi-asserted-by":"crossref","first-page":"556","DOI":"10.4172\/2155-6113.1000556","article-title":"Quantitative and functional antibody responses to the 13-valent conjugate and\/or 23-valent purified polysaccharide vaccine in aging HIV-infected adults","volume":"7","author":"Ohtola","year":"2016","journal-title":"J AIDS Clin Res"},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0007","unstructured":"European Centre for Disease Prevention and Control (ECDC). Invasive pneumococcal disease\u2014Annual epidemiological report for 2018. Stockholm, Sweden: ECDC; 2020. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/invasive-pneumococcal-disease-annual-epidemiological-report-2018 [accessed 4 January 2022]."},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0008","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/cid\/ciz226","article-title":"Immunogenicity of the currently recommended pneumococcal vaccination schedule in patients with inflammatory bowel disease","volume":"70","author":"van Aalst","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0009","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/cei.12299","article-title":"Response to pneumococcal vaccination in mannose-binding lectin-deficient adults with recurrent respiratory tract infections","volume":"177","author":"van Kessel","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"3 Suppl","key":"10.1016\/j.ijantimicag.2022.106629_bib0010","first-page":"S1","article-title":"Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy","volume":"130","author":"Orange","year":"2012","journal-title":"Asthma & Immunology. J Allergy Clin Immunol"},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0011","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ijid.2015.07.008","article-title":"The controversial impact of B cells subsets on immune response to pneumococcal vaccine in HIV-1 patients","volume":"38","author":"Tsachouridou","year":"2015","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0012","doi-asserted-by":"crossref","first-page":"8212","DOI":"10.4049\/jimmunol.178.12.8212","article-title":"Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease","volume":"178","author":"Hart","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0013","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15585\/mmwr.mm7104a1","article-title":"Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0014","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.4049\/jimmunol.2001133","article-title":"Impact of HIV-1 infection and antigen class on T follicular helper cell responses to pneumococcal polysaccharide\u2013protein conjugate vaccine-13","volume":"206","author":"Jha","year":"2021","journal-title":"J Immunol"},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0015","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.amepre.2021.01.023","article-title":"Higher-valency pneumococcal conjugate vaccines: an exploratory cost-effectiveness analysis in U.S. seniors","volume":"61","author":"Smith","year":"2021","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0016","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1016\/j.vaccine.2013.06.037","article-title":"Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults","volume":"31","author":"Smith","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0017","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1016\/j.vaccine.2021.07.004","article-title":"A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age","volume":"39","author":"Klein","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0018","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/QAD.0000000000003126","article-title":"V114-018 (PNEU-WAY) Study group. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV","volume":"36","author":"Mohapi","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0019","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1097\/QAD.0b013e3283389de5","article-title":"Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults","volume":"24","author":"Pe\u00f1aranda","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0020","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1097\/00002030-200309260-00002","article-title":"Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection","volume":"17","author":"Lange","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0021","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1006\/clim.2001.5164","article-title":"CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection","volume":"102","author":"Lange","year":"2002","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0022","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1097\/00002030-200209270-00002","article-title":"Limited immune restoration after 3 years\u2019 suppression of HIV-1 replication in patients with moderately advanced disease","volume":"16","author":"Valdez","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0023","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.vaccine.2014.01.047","article-title":"Carrier priming or suppression: understanding carrier priming enhancement of anti-polysaccharide antibody response to conjugate vaccines","volume":"32","author":"Pobre","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0024","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(14)70822-9","article-title":"Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study","volume":"14","author":"Andrews","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0091-6749(98)70089-2","article-title":"Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations","volume":"102","author":"Sorensen","year":"1998","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl","key":"10.1016\/j.ijantimicag.2022.106629_bib0026","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1093\/clinids\/3.Supplement_1.S184","article-title":"Assessment of the antibody response to pneumococcal vaccine in high-risk populations","volume":"3","author":"Landesman","year":"1981","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106629_bib0027","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922001418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922001418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:44:07Z","timestamp":1760377447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857922001418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0924857922001418"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106629","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine in people living with HIV on combination antiretroviral therapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106629","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106629"}}